An interdisciplinary team of Vanderbilt University researchers has received a two-year, $2-million federal grant to develop an “organ-on-chip” model for two genetic forms of epilepsy.

An enzyme in the gut – NAPE-PLD – is required for the action of signaling molecules that reduce food intake and weight gain.

Developed at Vanderbilt, VU319 is designed to precisely target a specific neuron receptor associated with cognitive function while avoiding potentially dangerous side effects.

H. Alex Brown, Ph.D., the Bixler-Johnson-Mayes Professor in the Department of Pharmacology at Vanderbilt University School of Medicine, died from cancer Tuesday, July 25, at his home. He was 56.

The identification of a genetic culprit for hypoplastic left heart syndrome could lead to new treatments for the condition.

A signaling molecule called interleukin-6 may be a therapeutic target to prevent vision loss or nerve degeneration in glaucoma, Vanderbilt researchers have discovered.

Ronald Emeson, Ph.D., is a three-time winner of the Teacher of the Year Award presented by graduate students in the Department of Pharmacology